linagliptin; metformin hydrochloride - Profile

What are the generic drug sources for linagliptin; metformin hydrochloride and what is the scope of patent protection?

Linagliptin; metformin hydrochloride is the generic ingredient in three branded drugs marketed by Boehringer Ingelheim, Dr Reddys, MSN, Sunshine, and Zydus Pharms, and is included in six NDAs. There are eleven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Linagliptin; metformin hydrochloride has three hundred and seven patent family members in forty-one countries.

There is one tentative approval for this compound.

Summary for linagliptin; metformin hydrochloride

International Patents:	307
US Patents:	11
Tradenames:	3
Applicants:	5
NDAs:	6
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for linagliptin; metformin hydrochloride

Generic filers with tentative approvals for LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		2.5MG;1GM	TABLET;ORAL
		2.5MG;850MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for LINAGLIPTIN; METFORMIN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JENTADUETO XR	Extended-release Tablets	linagliptin; metformin hydrochloride	2.5 mg/1000 mg 5 mg/1000 mg	208026	1	2018-03-28
JENTADUETO	Tablets	linagliptin; metformin hydrochloride	2.5 mg/500 mg 2.5 mg/850 mg 2.5 mg/1000 mg	201281	8	2015-05-04

US Patents and Regulatory Information for linagliptin; metformin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No					Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No					Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No					Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No					Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No					Y
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016		RX	Yes	No					Y

Expired US Patents for linagliptin; metformin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-002	Jan 30, 2012
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-003	Jan 30, 2012
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-002	Jan 30, 2012
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-003	Jan 30, 2012
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-001	May 27, 2016

EU/EMA Drug Approvals for linagliptin; metformin hydrochloride

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Jentadueto	linagliptin, metformin hydrochloride	EMEA/H/C/002279Treatment of adult patients with type-2 diabetes mellitus:Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.	Authorised	no	no	no	2012-07-19

International Patents for linagliptin; metformin hydrochloride

Country	Patent Number	Title	Estimated Expiration
Australia	2007247141
European Patent Office	3150204
Australia	2023201872
Japan	2016164161
Taiwan	I527816
Japan	6811203
China	102271673

Supplementary Protection Certificates for linagliptin; metformin hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1084705	C01084705/04	Switzerland		PRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 61893 08.03.2012
1084705	CA 2014 00065	Denmark		PRODUCT NAME: LINAGLIPTIN; REG. NO/DATE: EU/1/11/707/001-011 20110824
2187879	2017020	Norway		PRODUCT NAME: EMPAGLIFLOZIN OG LINAGLIPTIN; REG. NO/DATE: EU/1/16/1146-001-018 20161209
1730131	C01730131/03	Switzerland		PRODUCT NAME: EMPAGLIFLOZIN UND LINAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66132 29.03.2017
1532149	8/2012	Austria		PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION UND DESSEN SALZE, INSBES. LINAGLIPTIN; REGISTRATION NO/DATE: EU/1/11/707/001-011 (MITTEILUNG) 20110830
1532149	118 5013-2011	Slovakia		PRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: EU/1/11/707/001 - EU/1/11/707/011 20110824
1532149	C01532149/01	Switzerland		PRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 61893 08.03.2012

Analysis of the Investment Scenario, Market Dynamics, and Financial Trajectory for Linagliptin and Metformin Hydrochloride

Last updated: February 3, 2026

---

Summary

This report evaluates the investment prospects, market trends, and financial outlook for the combined pharmaceutical agents linagliptin and metformin hydrochloride. These drugs are pivotal in type 2 diabetes mellitus management, with each possessing established market positions and regulatory pathways. The analysis leverages current data on patent status, market demand, competitive landscape, regulatory environment, and pricing strategies to inform investment decisions.

Introduction

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor approved globally for type 2 diabetes management. Metformin hydrochloride remains the first-line therapy for diabetes, especially in combination therapies. Co-formulation of these drugs enhances adherence and simplifies treatment regimens, making them attractive for both pharmaceutical manufacturers and investors.

---

1. Current Market Size and Growth Trajectory

Parameter	Data (2022-2027)	Source
Global diabetic therapeutics market size	$70.0 billion	[1]
Compound annual growth rate (CAGR)	6.8%	[1]
Estimated market for metformin-based drugs	$24.5 billion	[2]
Estimated market for DPP-4 inhibitors	$13.7 billion	[3]
Projected combined market for linagliptin + metformin	$35.1 billion	(Approximation based on above)

Key observations:

• The increasing prevalence of type 2 diabetes, projected to reach 700 million globally by 2045, continues to drive demand.
• The adoption of fixed-dose combinations (FDCs), including linagliptin-metformin tablets, has received regulatory promotion, encouraging market growth.

---

2. Patent and Regulatory Landscape

2.1 Patent Status of Linagliptin and Metformin

Drug	Patent Expiry	Key Patent Details	Implication for Investors
Linagliptin	2027-2030	Patents expiry varies by jurisdiction	Opportunities for generic entry post-expiry
Metformin Hydrochloride	Patent expired (1990s)	First approved in 1957, generic available	Generics dominate the market, pressure on brand pricing

Note: Recent improvements in formulations (e.g., co-formulated FDCs) may be patent-protected, extending market exclusivity.

2.2 Regulatory Approvals

• Both drugs are approved by the US FDA, EMA, and other agencies.
• The FDA has approved several combination formulations, including JD-503 (linagliptin + metformin XR), providing market advantage.
• Variable regulatory pathways affect timing and market access, particularly in emerging markets.

---

3. Market Dynamics

3.1 Competitive Landscape

Competitors	Key Products	Market Share (2022)	Notes
Merck & Co. (Janssen)	Tradjenta (linagliptin), Janumet (linagliptin+metformin)	~25%	Leading in DPP-4 inhibitors with strong brand recognition
Novo Nordisk	Saxenda, Victoza, in combination therapy	-	Expanding into combination therapies, indirectly competing in diabetes segment
Generic manufacturers	Metformin, war supplementary DPP-4 inhibitors	~60-70%	Lower-cost options dominate in emerging markets

3.2 Market Drivers

• Rising diabetes prevalence, especially in Asia-Pacific and Latin America.
• Patient preference shifts toward oral fixed-dose combinations.
• Healthcare policies favoring biosimilars and generics to control costs.

3.3 Market Restraints and Challenges

• Patent cliffs approaching for linagliptin.
• Competitive pressures from inexpensive generics.
• Regulatory hurdles in approval and reimbursement processes.

---

4. Financial Trajectory and Revenue Projections

Parameter	2022 Actual	2027 Forecast	Note
Revenue from linagliptin-containing products	$9.1 billion	$11.8 billion	CAGR ~4.2% – driven by increasing adoption in combination therapies
Revenue from metformin (brand & generic)	$15.4 billion	$17.2 billion	Stable growth; volume-driven, with price compression for generics
Co-formulated drug segment (linagliptin + metformin XR)	$4.0 billion	$6.5 billion	Higher CAGR (~9%) due to market expansion and regulatory incentives

Assumptions include:

• Steady market penetration of fixed-dose combinations.
• Patent expiry impacts post-2027, increasing generic competition.
• Growth driven by emerging markets with increasing healthcare access.

---

5. Investment Opportunities and Risks

Opportunities:

• Launch of new fixed-dose formulations post-patent expiry.
• Geographic expansion, particularly in Asia and Africa.
• Strategic alliances for biosimilars and generics.
• Development of biosimilar and novel combination therapies.

Risks:

• Patent expiration leading to revenue erosion.
• Regulatory delays and reimbursement hurdles.
• Market saturation and pricing pressure.
• Pricing commoditization in generics markets.

---

6. Comparative Analysis: Linagliptin + Metformin versus Alternatives

Attribute	Combination (Linagliptin + Metformin)	Alternatives	Notes
Efficacy	High (Complementary mechanisms)	Monotherapy, other combination drugs	Preferred in patients requiring dual therapy
Safety Profile	Well-tolerated, with low hypoglycemia risk	Monitoring needed with some alternatives	Better adherence due to safety profile
Patent Status	Close to expiry for linagliptin	Generic availability of metformin	Post-2027, significant market entry of generics
Pricing	Premium over metformin alone	Competitive, especially in generics	Pricing deflation expected post-patent expiry

---

7. Market Entry and Strategic Positioning

• Post-Patent Strategies:

Approach	Rationale	Expected Impact
Development of biosimilars and generics	Cost competitiveness	Capturing price-sensitive markets
Innovation in delivery (e.g., mini-tablets, XRforms)	Differentiation and improved compliance	Extending market share
Geographic expansion into emerging markets	Population growth, diabetes prevalence	Accelerate revenue growth

• Regulatory Engagement:

Policy/Guideline	Impact on Market Dynamics	Strategic Response
Incentives for biosarals and generics	Increased competition post-patent expiration	Focus on cost leadership and differentiation
Reimbursement policies favoring combo drugs	Accelerate adoption in formal healthcare systems	Engage with payers early

---

8. Conclusion: Future Financial Trajectory and Investment Outlook

• Short-term (Next 1-2 Years): Solid revenue for branded formulations; patent protection maintains pricing power.
• Medium-term (3-5 Years): Increased generic competition post-2027; revenue dip anticipated unless differentiation strategies are implemented.
• Long-term (Beyond 5 Years): Market stabilization through biosimilar entry, new formulations, and expansion in emerging markets.

Investors should favor companies with robust pipeline strategies, strong regulatory positioning, and active geographic expansion plans. The transition period post-patent expiry presents both risks and opportunities; proactive adaptation is essential for maximizing returns.

---

Key Takeaways

• The combined market of linagliptin and metformin hydrochloride is projected to grow to over $35 billion by 2027, bolstered by demographic and policy trends.
• Patent expiration around 2027-2030 will catalyze generic entry, pressuring branded revenues but also opening opportunities for biosimilars and innovative formulations.
• Strategic focus on fixed-dose combinations, geographic expansion, and regulatory engagement will define the financial success of pharmaceutical entities in this segments.
• The competitive landscape favors diversification and cost leadership, especially with increasing importance of biologics and biosimilars post-patent.
• Market sustainability hinges on balancing innovation with cost-effective production and leveraging emerging markets growth.

---

FAQs

Q1. When is the patent expiry for linagliptin, and how will it impact the market?
Patent protection for linagliptin is expected to expire between 2027 and 2030 in key markets. Post-expiry, generic competitors will likely increase, driving down prices and reducing revenues for branded formulations.

Q2. How does the combination of linagliptin and metformin compare to other diabetes therapies?
The combination offers high efficacy with a favorable safety profile, notably lower hypoglycemia risk compared to some alternatives. It is preferred as a first- or second-line therapy, especially in patients requiring dual therapy.

Q3. What are the primary growth drivers for this market segment?
Increasing diabetes prevalence, patient preference for fixed-dose formulations, regulatory encouragement for combination drugs, and expansion into emerging markets are primary drivers.

Q4. What risks threaten the profitability of investments in these drugs?
Patent cliffs, intense price competition, regulatory delays, and market saturation are key risks potentially eroding margins.

Q5. Are biosimilars or generics expected to dominate the market post-2027?
Yes, post-patent expiry, biosimilars and generics will capture significant market share, potentially reducing prices and margins for originator products.

---

References

[1] MarketWatch, "Global Diabetes Therapeutics Market Forecast," 2022.
[2] IQVIA, "Metformin Market Analysis," 2022.
[3] MarketsandMarkets, "DPP-4 Inhibitors Market Size," 2022.